Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
- PMID: 27486590
- PMCID: PMC4949498
- DOI: 10.1016/j.jdcr.2016.05.002
Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
Keywords: CTLA-4, cytotoxic T-lymphocyte–associated antigen 4; PD-1, programmed death–1; immune-related adverse events; immunotherapy; irAEs, immune-related adverse events; lung cancer; sarcoidosis.
Figures
![Fig 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4949498/bin/gr1.gif)
![Fig 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4949498/bin/gr2.gif)
Similar articles
-
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.Oncologist. 2016 Oct;21(10):1230-1240. doi: 10.1634/theoncologist.2016-0055. Epub 2016 Jul 8. Oncologist. 2016. PMID: 27401894 Free PMC article. Review.
-
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.J Hepatol. 2018 Jun;68(6):1181-1190. doi: 10.1016/j.jhep.2018.01.033. Epub 2018 Feb 8. J Hepatol. 2018. PMID: 29427729
-
[Efficacy and Management of Adverse Events of Ipilimumab Including Combination Therapy with Nivolumab].Gan To Kagaku Ryoho. 2019 Jun;46(6):1017-1026. Gan To Kagaku Ryoho. 2019. PMID: 31273168 Japanese.
-
A Review of Immune-Mediated Adverse Events in Melanoma.Oncol Ther. 2019 Dec;7(2):101-120. doi: 10.1007/s40487-019-0096-8. Epub 2019 Jul 8. Oncol Ther. 2019. PMID: 32699983 Free PMC article. Review.
-
Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.Transl Lung Cancer Res. 2015 Oct;4(5):560-75. doi: 10.3978/j.issn.2218-6751.2015.06.06. Transl Lung Cancer Res. 2015. PMID: 26629425 Free PMC article. Review.
Cited by
-
Advance in pathogenesis of sarcoidosis: Triggers and progression.Heliyon. 2024 Mar 8;10(5):e27612. doi: 10.1016/j.heliyon.2024.e27612. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38486783 Free PMC article. Review.
-
Sarcoid-like reaction and hypothyroidism induced by PD-1 inhibitor treatment in metastatic renal cell carcinoma: a case report and literature review.BMC Pulm Med. 2024 Mar 8;24(1):123. doi: 10.1186/s12890-024-02943-9. BMC Pulm Med. 2024. PMID: 38459507 Free PMC article. Review.
-
Immunotherapy-induced exclusively cutaneous sarcoid-like reaction.BMJ Case Rep. 2023 Jul 18;16(7):e252766. doi: 10.1136/bcr-2022-252766. BMJ Case Rep. 2023. PMID: 37463781
-
Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies.Cancers (Basel). 2023 Jun 9;15(12):3126. doi: 10.3390/cancers15123126. Cancers (Basel). 2023. PMID: 37370736 Free PMC article. Review.
-
Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma.Cancers (Basel). 2023 Mar 31;15(7):2084. doi: 10.3390/cancers15072084. Cancers (Basel). 2023. PMID: 37046745 Free PMC article. Review.
References
-
- Reule R.B., North J.P. Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab. J Am Acad Dermatol. 2013;69(5):e272–e273. - PubMed
-
- Eckert A., Schoeffler A., Dalle S., Phan A., Kiakouama L., Thomas L. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology. 2009;218(1):69–70. - PubMed
-
- Vogel W.V., Guislain A., Kvistborg P., Schumacher T.N., Haanen J.B., Blank C.U. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol. 2012;30(2):e7–e10. - PubMed
-
- van den Eertwegh A.J., Versluis J., van den Berg H.P. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):509–517. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources